Kit - KIT proto-oncogene receptor tyrosine kinase Gene

中文名称：K IT 原癌基因受体酪氨酸激酶

种属: Rattus norvegicus

基因 ID: 64030 | 基因类型: protein coding

关于 Kit

Primary_assembly 14: 32,548,877-32,624,652 reverse strand.mRatBN7.2:CM026987.1

This gene has 2 transcripts (splice variants), 206 orthologues, 54 paralogues and is associated with 72 phenotypes. Biased expression in Lung (RPKM 35.8), Brain (RPKM 125.4) and 9 other tissues.

功能概要

该基因编码的蛋白可启动蛋白酪氨酸激酶活性。参与多个过程，包括配子生成；胃肠系统平滑肌收缩的正向调节；和蛋白质磷酸化。位于顶体囊泡；质膜的细胞质侧；和质膜的外侧。用于研究再生障碍性贫血和男性不育症。急性胰腺炎和腹裂的生物标志物。该基因的人类直系同源物与多种疾病有关，包括急性髓性白血病；胃肠道间质瘤；生殖细胞癌（多发性）；花斑病;和肾细胞癌。与人类 KIT 同源（KIT 原癌基因，受体酪氨酸激酶）。 [由基因组资源联盟提供，2022 年 4 月]

Enables protein tyrosine kinase activity. Involved in several processes, including gamete generation; positive regulation of gastro-intestinal system smooth muscle contraction; and protein phosphorylation. Located in acrosomal vesicle; cytoplasmic side of plasma membrane; and external side of plasma membrane. Used to study aplastic anemia and male infertility. Biomarker of acute pancreatitis and gastroschisis. Human ortholog(s) of this gene implicated in several diseases, including acute myeloid leukemia; gastrointestinal stromal tumor; germ cell Cancer (multiple); piebaldism; and renal cell carcinoma. Orthologous to human KIT (KIT proto-oncogene, receptor tyrosine kinase). [provided by Alliance of Genome Resources, Apr 2022]

Kit 基因产物(1)

mRNA	Protein	Name
NM_022264.2	NP_071600.1	mast/stem cell growth factor receptor Kit precursor

Kit 蛋白结构

Ig_3

IgI_4_SCFR

PKc_like

0
200
400
600
800
978 a.a.

蛋白主名

其他名称

mast/stem cell growth factor receptor Kit

Kit oncogene	c-kit receptor tyrosine kinase
protein kinase	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog

重组 Kit 蛋白

目录号	产品名	蛋白编号	纯度
HY-P74337	CD117/c-kit Protein, Rat (HEK293, His)	Q63116 (M1-T522)	≥95%
HY-P74338	CD117/c-kit Protein, Rat (HEK293, Fc)	Q63116 (M1-T522)	≥95%

相关产品

Approval

生物活性分子 (28)

目录号	产品名	作用方式	纯度	是否罕见病
HY-10201	Sorafenib		99.92%	是
HY-10981	Lenvatinib	Inhibitor	99.84%	是
HY-16749	Pexidartinib		99.64%	是
HY-10331	Regorafenib		99.93%	是
HY-15463	Imatinib		99.95%	是
HY-13016	Cabozantinib		99.96%	是
HY-10230	Midostaurin		99.95%	是
HY-10208	Pazopanib		99.91%	是
HY-10201A	Sorafenib Tosylate		99.91%	是
HY-50946	Imatinib Mesylate		99.98%	是
HY-101561	Avapritinib	Inhibitor	99.94%	是
HY-112306	Ripretinib		99.33%	是
HY-10209	Masitinib		99.98%	是
HY-10981A	Lenvatinib mesylate	Inhibitor	99.86%	是
HY-16749A	Pexidartinib hydrochloride		99.86%	是
HY-12009	Pazopanib Hydrochloride		99.88%	是
HY-12044	Cabozantinib S-malate		99.90%	是
HY-13308	Regorafenib Hydrochloride		99.58%	是
HY-10331A	Regorafenib monohydrate		99.96%	是
HY-13904	Flumatinib	Inhibitor	99.94%	否
HY-10209A	Masitinib mesylate		99.83%	是
HY-13311A	Infigratinib phosphate	Inhibitor	99.74%	是
HY-10330A	Toceranib phosphate	Inhibitor	98.54%	否
HY-10330	Toceranib	Inhibitor	96.86%	否
HY-B1684	Mebrofenin		99.88%	否
HY-10331B	Regorafenib mesylate		/	否
HY-13016A	Cabozantinib hydrochloride		/	否
HY-50946R	Imatinib Mesylate (Standard)		/	否

Clinical Phase

生物活性分子 (28)

目录号	产品名	作用方式	纯度	Phase
HY-13905	Flumatinib mesylate	Inhibitor	99.87%	Phase 4
HY-50905	Dovitinib	Inhibitor	99.94%	Phase 3
HY-10205	Cediranib		99.58%	Phase 3
HY-16961	Sitravatinib	Inhibitor	99.59%	Phase 3
HY-145557	Bezuclastinib	Inhibitor	98.59%	Phase 3
HY-136256	Vimseltinib	Inhibitor	99.08%	Phase 3
HY-13049	Cediranib maleate		99.95%	Phase 3
HY-10228	Motesanib	Inhibitor	99.96%	Phase 3
HY-124526	Chiauranib	Inhibitor	99.28%	Phase 3
HY-10207	Dovitinib lactate	Inhibitor	99.62%	Phase 3
HY-108713	Famitinib		98.43%	Phase 3
HY-152839	Elenestinib	Inhibitor	98.82%	Phase 3
HY-10229	Motesanib Diphosphate	Inhibitor	99.64%	Phase 3
HY-16961A	Sitravatinib malate	Inhibitor	/	Phase 3
HY-B0062	Dovitinib lactate hydrate	Inhibitor	/	Phase 3
HY-108713A	Famitinib malate		/	Phase 3
HY-13024	Rebastinib		99.91%	Phase 2
HY-109086	Edicotinib	Inhibitor	98.78%	Phase 2
HY-10206	Amuvatinib		99.47%	Phase 2
HY-10202	Tandutinib		99.48%	Phase 2
HY-109190	Seralutinib	Inhibitor	99.77%	Phase 2
HY-10527	Telatinib	Inhibitor	99.60%	Phase 2
HY-10202A	Tandutinib hydrochloride		99.78%	Phase 2
HY-10527C	Telatinib mesylate	Inhibitor	99.46%	Phase 2
HY-10206A	Amuvatinib hydrochloride	Inhibitor	/	Phase 2
HY-10204	OSI-930		98.57%	Phase 1
HY-12010	BMS-599626 Hydrochloride	Inhibitor	99.68%	Phase 1
HY-10251	BMS-599626	Inhibitor	/	Phase 1

抗体抑制剂 (1)

目录号	产品名	作用方式	纯度	Phase
HY-P99462	Barzolvolimab	Inhibitor	99.78%	Phase 2

Pre-clinical Phase

生物活性分子 (85)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-10514	BX795		99.06%	否
HY-101443	ISCK03	Inhibitor	99.50%	否
HY-131339	SP-96	Inhibitor	99.42%	否
HY-132166	M4205	Inhibitor	99.47%	否
HY-10501	SU14813	Inhibitor	99.63%	否
HY-112802	AZD3229	Inhibitor	99.69%	否
HY-13894	Tyrphostin AG1296		99.69%	否
HY-13838	PLX647	Inhibitor	99.79%	否
HY-G0017	N-Desmethyl imatinib		99.16%	否
HY-10873	N-Desethyl Sunitinib		99.63%	否
HY-10408	Ki20227	Inhibitor	99.17%	否
HY-15240	c-Kit-IN-1	Inhibitor	98.83%	否
HY-I0678	Regorafénib N-oxyde (M2)		98.27%	否
HY-10501A	SU14813 maleate	Inhibitor	99.04%	否
HY-101219	VEGFR-IN-1	Inhibitor	98.42%	否
HY-112452	SU11652		99.06%	否
HY-103274	PD180970		99.27%	否
HY-15463S1	Imatinib-d4		99.97%	否
HY-15813	FIIN-1	Inhibitor	99.11%	否
HY-148794	Risvodetinib	Inhibitor	99.21%	否
HY-13493	AC710	Inhibitor	98.56%	否
HY-112615	NAMPT inhibitor-linker 1		98.08%	否
HY-112616	NAMPT inhibitor-linker 2	Inhibitor	98.11%	否
HY-13016S	Cabozantinib-d6		98.14%	否
HY-103032	Multi-kinase inhibitor 1	Inhibitor	99.34%	否
HY-10981S	Lenvatinib-d4	Inhibitor	99.59%	否
HY-138813	N-Desethyl Sunitinib hydrochloride		99.77%	否
HY-18302	c-Kit-IN-5-1	Inhibitor	98.16%	否
HY-18179	AZD2932	Inhibitor	99.04%	否
HY-112802A	AZD3229 Tosylate	Inhibitor	99.80%	否
HY-10208S	Pazopanib-d6		≥98.0%	否
HY-10230S	Midostaurin-d5	Inhibitor	≥98.0%	否
HY-123450	S116836		99.65%	否
HY-133980	O-Demethyl Lenvatinib		/	否
HY-133980A	O-Demethyl Lenvatinib hydrochloride		95.54%	否
HY-136201	Sodium Glucoheptonate		≥98.0%	否
HY-15198	KG5	Inhibitor	99.79%	否
HY-15463S	Imatinib-d8		99.85%	否
HY-15463S2	Imatinib-d3 hydrochloride		95.19%	否
HY-156619	Labuxtinib	Inhibitor	99.76%	否
HY-18317	JNJ-38158471	Inhibitor	97.02%	否
HY-101034	CHMFL-ABL/KIT-155		/	否
HY-128589	CHMFL-KIT-033	Inhibitor	/	否
HY-128602	c-Kit-IN-2	Inhibitor	/	否
HY-10873S	N-Desethyl Sunitinib-d5		/	否
HY-10201S2	Sorafenib-13C,d3		98.35%	否
HY-10208S1	Pazopanib-13C,d3		/	否
HY-10331S	Regorafenib-d3		≥98.0%	否
HY-10331S1	Regorafenib-13C,d3		/	否
HY-10981S1	Lenvatinib-d5	Inhibitor	/	否
HY-110071	APcK110	Inhibitor	/	否
HY-110272	Vatalanib succinate	Inhibitor	/	否
HY-117873	KBP-7018	Inhibitor	/	否
HY-12009S	Pazopanib-13C,d3 hydrochloride		/	否
HY-13016S1	Cabozantinib-d4		/	否
HY-131275	Imatinib Impurity E		96.05%	否
HY-132451S	(R,S)-4-Hydroxy Cyclophosphamide-d4 Preparation Kit		/	否
HY-13342AS	Apatinib-d8 free base		92.56%	否
HY-13645	Henatinib	Inhibitor	/	否
HY-13838A	PLX647 dihydrochloride	Inhibitor	/	否
HY-13904S	Flumatinib-d3	Inhibitor	/	否
HY-139996	Pomalidomide-C5-Dovitinib		/	否
HY-143894	FLT3-IN-11	Inhibitor	/	否
HY-143895	FLT3-IN-12	Inhibitor	/	否
HY-147864	c-Fms-IN-12		/	否
HY-149019	Antitumor agent-70		/	否
HY-149415	Multi-kinase-IN-5	Inhibitor	/	否
HY-150026	Multi-kinase-IN-2		/	否
HY-156470	Multi-kinase-IN-6		/	否
HY-15814	HG-7-85-01		99.94%	否
HY-160689	GW694590A	Inhibitor	/	否
HY-160765	WNTinib		/	否
HY-18949	JI6	Inhibitor	/	否
HY-50905S	Dovitinib-d8	Inhibitor	/	否
HY-G0017A	N-Desmethyl imatinib mesylate		/	否
HY-G0017S1	N-Desmethyl imatinib-d4		/	否
HY-I0678S	Regorafénib N-oxyde-d3 (M2)		/	否
HY-I0678S1	Regorafénib N-oxyde (M2)-13C,d3		/	否
HY-RS07319	KIT Human Pre-designed siRNA Set A		/	否
HY-RS07320	Kit Mouse Pre-designed siRNA Set A		/	否
HY-RS07321	Kit Rat Pre-designed siRNA Set A		/	否
HY-10330S	Toceranib-d8	Inhibitor	/	否
HY-116116	Tafetinib	Inhibitor	/	否
HY-13493A	AC710 Mesylate	Inhibitor	/	否
HY-111947	c-Fms-IN-6	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Kit	NCBI	NCBI:3815
Mus musculus	Kit	NCBI	NCBI:16590
Macaca mulatta	Kit	NCBI	NCBI:696759

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。沪(浦)应急管危经许[2021]201709(QFYS)	站点地图隐私声明
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.	沪ICP备15051369号-4

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。沪(浦)应急管危经许[2021]201709(QFYS)

站点地图隐私声明

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.